Lilly - TechWire

Lilly

2025.08.01

19:45

Novo Nordisk and Eli Lilly rose in pre-market trading as the US may consider insurance coverage for weight loss drugs.

Novo Nordisk shares rose 1.9% in pre-market trading, while Eli Lilly and Company rose 1.5% following reports that the United States will consider insurance coverage for weight loss drugs.

19:45

Novo Nordisk (NVO.N) rose 1.9% in premarket trading, while Eli Lilly (LLY.N) rose 1.5% following reports that the United States will consider insurance coverage for weight loss drugs.

04:13

US stocks close: All three major stock indexes fall, while new stock Figma soars 250%

The three major US stock indices closed lower, with the Dow Jones Industrial Average down 0.74%, the Nasdaq down 0.03%, and the S&P 500 down 0.37%. Popular technology stocks saw mixed gains and losses, with Meta gaining over 11% and Microsoft rising nearly 4%, though its market capitalization fell below $40,000. Arm fell over 13%, Tesla fell over 3%, and Google and Broadcom fell over 2%. Semiconductor equipment and materials, and weight loss drug stocks saw the largest declines, with Novo Nordisk down nearly 6%, KLA-Tencor down nearly 5%, ASML down over 3%, and Eli Lilly and Pfizer down over 2%. Design software giant Figma saw its stock price surge 250% on its first day of trading.

01:43

Eli Lilly and Company turned to decline.

01:35

The White House: Calling on Eli Lilly to take action within 60 days, if it refuses, it will use tools to protect the rights of American citizens.

2025.07.30

04:11

US stock market closes: All three major stock indexes fall, Novo Nordisk falls more than 20%

The three major US stock indices closed lower, with the Dow Jones Industrial Average down 0.46%, the Nasdaq down 0.38%, and the S&P 500 down 0.3%. Most popular technology stocks fell, with Meta dropping over 2%, Intel, Apple, and Tesla down over 1%, and AMD up over 2%. Weight loss drug and integrated logistics sectors plummeted, with Novo Nordisk down over 21%, UPS down over 10%, Eli Lilly down over 5%, and FedEx down over 3%. The oil and gas sector strengthened, with ExxonMobil, Shell, and Imperial Oil rising over 1%.

2025.07.29

21:47

Eli Lilly shares fell 5.8%

Eli Lilly shares fell 5.8% after rival Novo Nordisk cut its sales growth and operating profit forecasts for 2025.

21:46

Eli Lilly (LLY.N) shares fell 5.8% after rival Novo Nordisk cut its sales growth and operating profit forecasts for 2025.

19:20

Eli Lilly (LLY.N) fell 2.6% in premarket trading after rival Novo Nordisk cut its sales growth and operating profit forecasts for 2025.

2025.07.28

17:13

Eli Lilly's GLP-1 drug adds new indication for combined insulin therapy

On July 28, reporters learned that Eli Lilly's GLP-1 drug telportin injection (trade name: Mufengda) was recently approved by the China National Drug Administration, with a new indication: used in combination with insulin (with or without oral hypoglycemic drugs) on the basis of diet control and exercise to improve blood sugar control in adult patients with type 2 diabetes (T2DM).

2025.07.26

00:07

Eli Lilly (LLY.N) rose 0.14% and Novo Nordisk (NVO.N) rose 0.88% as bipartisan U.S. lawmakers put pressure on the U.S. Food and Drug Administration to crack down on compounded and counterfeit GLP-1 drugs.

2025.07.10

07:09

Nearly 10 billion US dollars flow into AI pharmaceutical new drug research and development, pressing the acceleration key

According to the Securities Times, AI pharmaceuticals have recently attracted market attention due to frequent project cooperation and investment and financing events. The reporter learned from the industry that as AI accelerates its penetration into the pharmaceutical industry, the research and development of innovative drugs has ushered in a milestone progress, and the results of AI pharmaceuticals have blossomed in many places. At the same time, AI pharmaceuticals are facing commercial difficulties, and it will take time to solve them. Recently, large orders in the field of AI pharmaceuticals have frequently appeared. On June 11, Novo Nordisk reached a US$812 million cooperation with AI pharmaceutical company Deep Apple Therapeutics; on June 12, Eli Lilly and Juvena Therapeutics (an American AI pharmaceutical company) signed an agreement of more than US$650 million; on June 13, AstraZeneca (AZ) and Shijiazhuang Pharmaceutical Group reached a cooperation of up to US$5.3 billion to use Shijiazhuang Pharmaceutical Group's AI drug discovery platform to develop small molecule drug candidates. On June 23, Jingtai Holdings, a leading domestic AI pharmaceutical company, signed a multi-billion dollar pipeline licensing cooperation letter of intent with DoveTree LLC (a company founded by Gregory Verdine, a legendary entrepreneur and investor in the US pharmaceutical industry); on the same day, AI pharmaceutical company Formation Bio announced that its subsidiary had licensed the oral dual JAK/SYK inhibitor gusacitinib to Sanofi, with the maximum cooperation amount reaching 545 million euros. In less than a month, nearly 10 billion US dollars flowed into the AI pharmaceutical industry, causing a stir in the industry.

2025.07.03

15:50

New indication for telportin approved in China

Eli Lilly announced that Mufengda (tilpoxetine injection) has been approved by the China National Medical Products Administration (NMPA) as the first and currently the only prescription drug for the treatment of moderate to severe obstructive sleep apnea (OSA) in obese adult patients. Tipoxetine can improve sleep disorders in obese adult patients with moderate to severe obstructive sleep apnea. The use of this indication requires control of diet and increased exercise.

2025.06.26

22:49

The first domestically produced GLP-1 weight loss innovative drug is about to be approved, and the unofficial price has been revealed

Reporters learned from multiple sources that the weight loss indication of Masdu peptide injection, the first domestically produced GLP-1 weight loss innovative drug developed by Innovent Biologics, is expected to be approved as early as this week. As of the close of June 26, Innovent Biologics' stock price fell by about 5%. Innovent Biologics previously publicly stated that both weight loss and glucose-lowering indications of Masdu peptide are expected to be approved this year. Masdu peptide is the world's first GCG/GLP-1 dual receptor agonist weight loss drug. After approval, it is expected to break the current global weight loss drug competition dominated by multinational giants Novo Nordisk and Eli Lilly, and is expected to improve the accessibility of GLP-1 weight loss drugs.

2025.06.23

17:59

Morgan Stanley maintains "overweight" rating on Eli Lilly

Morgan Stanley maintained its "overweight" rating on Eli Lilly with a target price of $1,133.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.
                            2025-07-30

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.
                            2025-07-30

                                    BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.
                            2025-08-01